Cometas Noticias 19 noviembre 2025

January 19, 2026, 2:20 PM EST. Elekta's Evo CT-Linac has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA), enabling its use in radiation oncology across the United States. The system integrates high-quality CT imaging with linear accelerator functions, allowing for clearer tumor visualization during treatments. This approval advances Elekta's strategy to expand in the U.S. market by offering AI-driven imaging and personalized radiation therapy solutions. Since the announcement, Elekta shares (EKTAY) rose 3.7%, outpacing sector and S&P 500 gains over six months. The Evo system features Iris, AI-enhanced imaging that improves image clarity and treatment accuracy while being compatible with existing equipment. This innovation may boost clinical outcomes, operational efficiency, and Elekta's market positioning in cancer care technology.